- Home
- BTDR vs ADMA Comparison
BTDR vs ADMA Comparison
Compare BTDR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTDR
- ADMA
- Stock Information
- Founded
- BTDR 2021
- ADMA 2004
- Country
- BTDR Singapore
- ADMA United States
- Employees
- BTDR N/A
- ADMA N/A
- Industry
- BTDR EDP Services
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTDR Technology
- ADMA Health Care
- Exchange
- BTDR Nasdaq
- ADMA Nasdaq
- Market Cap
- BTDR 3.6B
- ADMA 4.1B
- IPO Year
- BTDR N/A
- ADMA N/A
- Fundamental
- Price
- BTDR $21.71
- ADMA $16.16
- Analyst Decision
- BTDR Strong Buy
- ADMA Strong Buy
- Analyst Count
- BTDR 10
- ADMA 4
- Target Price
- BTDR $20.50
- ADMA $21.25
- AVG Volume (30 Days)
- BTDR 7.7M
- ADMA 2.4M
- Earning Date
- BTDR 11-18-2024
- ADMA 02-26-2025
- Dividend Yield
- BTDR N/A
- ADMA N/A
- EPS Growth
- BTDR N/A
- ADMA N/A
- EPS
- BTDR N/A
- ADMA 0.28
- Revenue
- BTDR $395,612,000.00
- ADMA $382,809,000.00
- Revenue This Year
- BTDR N/A
- ADMA $66.90
- Revenue Next Year
- BTDR $72.04
- ADMA $13.76
- P/E Ratio
- BTDR N/A
- ADMA $57.65
- Revenue Growth
- BTDR 19.58
- ADMA 63.39
- 52 Week Low
- BTDR $5.23
- ADMA $5.02
- 52 Week High
- BTDR $26.99
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- BTDR 55.09
- ADMA 37.26
- Support Level
- BTDR $16.39
- ADMA $15.92
- Resistance Level
- BTDR $23.19
- ADMA $17.32
- Average True Range (ATR)
- BTDR 2.68
- ADMA 0.87
- MACD
- BTDR -0.34
- ADMA -0.15
- Stochastic Oscillator
- BTDR 50.19
- ADMA 7.21
About BTDR Bitdeer Technologies Group
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.